Xanomeline/trospium

DRUG2 trials

Sponsors

Vanguard Research Group, European Group for Research In Schizophrenia

Conditions

Cognitive ImpairmentSchizophreniaSchizophrenia; Psychosis

Phase 3

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

Not yet recruitingNCT07084831

European Group for Research In SchizophreniaCognitive Impairment, Schizophrenia; Psychosis

Start: 2027-01-01End: 2029-07-01Target: 171Updated: 2026-05-13

Phase 4

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

Not yet recruitingNCT06923891

Vanguard Research GroupSchizophrenia

Start: 2025-04-16End: 2026-11-30Target: 172Updated: 2025-04-11

Related Papers

Resilience factors, pain, and physical activity in adolescent chronic musculoskeletal pain: Design and protocol of a pilot phase 2 single-group, non-randomized clinical trial

PLoS ONE2026-07-30

Resilience factors, pain, and physical activity in adolescent chronic musculoskeletal pain: design and protocol of a pilot phase 2 single-group, non-randomized clinical trial

medRxiv2026-06-22